Prime Medicine Files 8-K

Ticker: PRME · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1894562

Prime Medicine, Inc. 8-K Filing Summary
FieldDetail
CompanyPrime Medicine, Inc. (PRME)
Form Type8-K
Filed DateJan 13, 2025
Risk Levellow
Pages2
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 8-k

TL;DR

Prime Medicine filed an 8-K, likely with updates. Keep an eye out for details.

AI Summary

On January 13, 2025, Prime Medicine, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.

Why It Matters

This filing indicates that Prime Medicine, Inc. is providing updates or disclosures to the SEC, which could contain important information for investors.

Risk Assessment

Risk Level: low — The provided text is a standard SEC filing header and does not contain information about specific risks or material events.

Key Players & Entities

  • Prime Medicine, Inc. (company) — Registrant
  • 0001894562 (company) — Central Index Key
  • 001-41536 (company) — SEC File Number
  • 60 First Street, Cambridge, MA 02139 (company) — Business Address
  • 617-465-0013 (company) — Business Phone

FAQ

What is the primary purpose of this 8-K filing for Prime Medicine, Inc.?

The filing is primarily for Regulation FD Disclosure and to report Financial Statements and Exhibits.

When was this 8-K report filed?

The report was filed on January 13, 2025.

What is Prime Medicine, Inc.'s state of incorporation?

Prime Medicine, Inc. is incorporated in Delaware.

What is the principal executive office address for Prime Medicine, Inc.?

The principal executive office is located at 60 First Street, Cambridge, MA 02139.

What is the SIC code for Prime Medicine, Inc.?

The Standard Industrial Classification code is 2836, for BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).

Filing Stats: 537 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2025-01-13 08:01:07

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 13, 2025, Prime Medicine, Inc. (the "Company") posted an updated corporate presentation to its website at https://investors.primemedicine.com/news-events. A copy of the corporate presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K, which is incorporated herein by reference. Reference to the Company's website is for inactive textual reference only and the content of the website should not be deemed incorporated by reference into this Current Report on Form 8-K. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 - Financial Statements and Exhibits

Item 9.01 - Financial Statements and Exhibits (d) Exhibits Exhibit Number Description 99.1 Corporate Presentation, dated January 2025, furnished herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 13, 2025 Prime Medicine, Inc. By: /s/ Keith Gottesdiener Name: Keith Gottesdiener, M.D. Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.